Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Mofegiline
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
Other names | MDL-72,974A |
Routes of administration |
Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 1–3 hours |
Excretion | Urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C11H13F2N |
Molar mass | 197.229 g·mol−1 |
3D model (JSmol) | |
| |
|
Mofegiline (MDL-72,974) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) which was under investigation for the treatment of Parkinson's disease and Alzheimer's disease, but was never marketed.
See also
Food antioxidants |
|
---|---|
Fuel antioxidants | |
Measurements |
AChE inhibitor medications | |
---|---|
Other medications | |
Experimental BACE inhibitors |
Dopaminergics |
|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Anticholinergics | |||||||||||
Others | |||||||||||
|